middle.news
Neuren Secures US Patent for NNZ-2591, Advancing Treatment for Pitt Hopkins Syndrome
9:35am on Thursday 26th of June, 2025 AEST
•
Healthcare
Read Story
Neuren Secures US Patent for NNZ-2591, Advancing Treatment for Pitt Hopkins Syndrome
9:35am on Thursday 26th of June, 2025 AEST
Key Points
US patent allowed for NNZ-2591 with expiry in April 2040
Positive Phase 2 trial outcomes in Pitt Hopkins syndrome patients
FDA granted Orphan Drug and Fast Track designations
Next development steps to be discussed with FDA
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE